Cipher Pharmaceuticals Inc
Research Cipher Pharmaceuticals Inc (CPH) on Bullrun: valuation model: 41.6% undervalued, market cap CAD 423.27M, P/E 9.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCPH
- ExchangeTO
- CountryCanada
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCAD
- Valuation signal41.6% undervalued
- Market capCAD 423.27M
- P/E9.9
- Financial periodQ4 2025
- RevenueCAD 12.22M
- Net incomeCAD 13.31M
- Free cash flowCAD 8.61M
- Gross margin81.1%
Valuation Snapshot
Bullrun's latest valuation model marks Cipher Pharmaceuticals Inc as 41.6% undervalued; latest market cap is CAD 423.27M; P/E is 9.9.
About Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women;
Frequently asked questions
Is Cipher Pharmaceuticals Inc overvalued or undervalued?
Bullrun's valuation model currently marks Cipher Pharmaceuticals Inc as 41.6% undervalued.
What is Cipher Pharmaceuticals Inc's market cap?
Cipher Pharmaceuticals Inc's market capitalization is CAD 423.27M.
What is Cipher Pharmaceuticals Inc's P/E ratio?
Cipher Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 9.9.
What does Cipher Pharmaceuticals Inc do?
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne;